Literature DB >> 7774629

Soluble mouse major histocompatibility complex class II molecules produced in Drosophila cells.

H J Wallny1, G Sollami, K Karjalainen.   

Abstract

We have exploited Drosophila melanogaster Schneider cells and compatible inducible expression vectors to produce large amounts of secreted major histocompatibility complex (MHC) class II molecules (I-Ed). A simple two-step purification protocol was developed. In the first step, recombinant molecules were enriched using a monoclonal anti-class II antibody column followed by a nickel chelate column which further purified and concentrated the recombinant protein to several mg/ml. Characterization of the purified material indicates that the molecules are correctly assembled into alpha beta heterodimers. Further analysis shows that the recombinant MHC class II molecules are devoid of endogenous peptides and, therefore, homogeneous peptide/MHC complexes could be prepared by adding exogenous I-Ed-specific peptides at slightly acidic pH. Upon peptide addition, molecules underwent a conformational change into a more compact form revealed by gel filtration analysis. In addition, the peptide/MHC complexes were biologically active. As little as 10 ng of these complexes coated on plastic from a 100 ng/ml solution were sufficient to trigger antigen-specific T cell hybridomas. These MHC class II molecules, together with various forms of soluble T cell receptor (TcR) proteins, provide valuable tools to analyze the molecular details of TcR/antigen recognition.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7774629     DOI: 10.1002/eji.1830250520

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  8 in total

1.  Antigen targeting to major histocompatibility complex class II with streptococcal mitogenic exotoxin Z-2 M1, a superantigen-based vaccine carrier.

Authors:  Fiona J Radcliff; Jacelyn M S Loh; Birgit Ha; Diana Schuhbauer; James McCluskey; John D Fraser
Journal:  Clin Vaccine Immunol       Date:  2012-02-01

2.  Soluble HLA-DQ2 expressed in S2 cells copurifies with a high affinity insect cell derived protein.

Authors:  Ulrike Jüse; Burkhard Fleckenstein; Elin Bergseng; Ludvig M Sollid
Journal:  Immunogenetics       Date:  2008-11-06       Impact factor: 2.846

3.  Supported Lipid Bilayer Technology for the Study of Cellular Interfaces.

Authors:  Travis J Crites; Michael Maddox; Kartika Padhan; James Muller; Calvin Eigsti; Rajat Varma
Journal:  Curr Protoc Cell Biol       Date:  2015-09-01

4.  Activation of the Flt3 signal transduction cascade rescues and enhances type I interferon-producing and dendritic cell development.

Authors:  Nobuyuki Onai; Aya Obata-Onai; Roxane Tussiwand; Antonio Lanzavecchia; Markus G Manz
Journal:  J Exp Med       Date:  2006-01-17       Impact factor: 14.307

5.  A mutational analysis of the binding of staphylococcal enterotoxins B and C3 to the T cell receptor beta chain and major histocompatibility complex class II.

Authors:  L Leder; A Llera; P M Lavoie; M I Lebedeva; H Li; R P Sékaly; G A Bohach; P J Gahr; P M Schlievert; K Karjalainen; R A Mariuzza
Journal:  J Exp Med       Date:  1998-03-16       Impact factor: 14.307

6.  Crucial role for BAFF-BAFF-R signaling in the survival and maintenance of mature B cells.

Authors:  Melanie Rauch; Roxane Tussiwand; Nabil Bosco; Antonius G Rolink
Journal:  PLoS One       Date:  2009-05-06       Impact factor: 3.240

7.  Annexin XIIIb associates with lipid microdomains to function in apical delivery.

Authors:  F Lafont; S Lecat; P Verkade; K Simons
Journal:  J Cell Biol       Date:  1998-09-21       Impact factor: 10.539

8.  Increased yields and biological potency of knob-into-hole-based soluble MHC class II molecules.

Authors:  Pau Serra; Nahir Garabatos; Santiswarup Singha; César Fandos; Josep Garnica; Patricia Solé; Daniel Parras; Jun Yamanouchi; Jesús Blanco; Meritxell Tort; Mireia Ortega; Yang Yang; Kristofor K Ellestad; Pere Santamaria
Journal:  Nat Commun       Date:  2019-10-29       Impact factor: 14.919

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.